General administrative expenses and R&D expenses increased at 7% and 12% respectively. And, the total SG&A expenses increased at 8% year on year.

Transcription

1

2 First of all, thanks to continuously strong sales in intervention system and smooth recovery in blood management, the consolidated net sales was billion yen, up by 4% year on year. While Terumo benefited from cost reduction initiatives and a shift toward highly profitable products, the price erosion and an additional cost for US TCVS s quality management system improvement due to additional data requirement by FDA had a negative impact, resulting in gross profit margin at 51.1%, down by 1.8 point year on year. General administrative expenses and R&D expenses increased at 7% and 12% respectively. And, the total SG&A expenses increased at 8% year on year. As a result, operating income totaled 53.2 billion yen, down by 16% year on year. While ordinary income was affected favorably by the depreciation of yen, the interest payments had a negative impact. As a result, it decreased 13% year on year to 51.4 billion yen. Net income amounted to record-high 47 billion yen due to corporate tax drop associated with restructuring of US subsidiaries. 2

3 Sales in Japan dropped 2% year on year due to declined sales of Nobori DES owing to the release of new products by competitors and revision of reimbursement price in Japan. Sales outside Japan increased 10% year on year. If excluding the impact of foreign exchange, it increased 8%. The ratio of sales outside Japan increased 3% to 54%. 3

4 As for the sales by business segment, General Hospital increased 2% year on year. Cardiac & Vascular increased 6%. At local currency basis, it increased 4% year on year. Blood Management increased 4%. At local currency basis, it increased 3%. For the details of each business performance, we will explain them by region in the next slide. 4

5 With General Hospital, sales in Japan remained steady all for infusion line related products, pharmaceuticals & nutrition and drug & device, resulting increase at 2% year on year. Regarding Cardiac & Vascular business, sales in Japan showed a sign of recovery momentum while reimbursement price revision and sales decline of Nobori had a negative impact, however, eventually decreased 13% year on year. Instead, outside Japan, intervention system continuously drove the sales in all region, especially in US and Europe, it grew at double digit. And, in China, intervention system increased 29%, which is higher than local PCI growth. With Blood Management, sales in Japan decreased 3% due to the impact of inventory adjustment by Japan Red Cross in preparation p for its IT system change. While a demand of transfusion was lowered by economic downturn in US, sales outside Japan grew at 4% without foreign exchange, driven by continuously strong therapeutic apheresis. Overall blood management business increased 3% year on year. 5

6 General administrative expense ratio against sales was 31.2%, up by 0.9%. R&D expenses, mainly for cardiac & vascular, increased 12% to 27.1 billion yen. 6

7 For the details of SG&A expenses, salaries & wages increased by 4.6 billion yen, consisting of 3.5 billion yen of real increase and 1.1 billion yen of foreign exchange impact. Primarily in fast growing segment, Cardiac & Vascular and Blood Management, the number of employees increased for sales expansion and quality management system improvement. And, Others increased by 1.9 billion yen, consisting of 0.4 billion yen of foreign exchange impact and 1.5 billion yen of real increase. That was mainly due to the cost for business integration in blood management and IT infrastructure improvement. 7

8 Looking into operating income variance analysis, it can be seen that operating income improvement could not absorb a price erosion including the reimbursement price revision in Japan. Furthermore, extra cost for TCVS s quality management improvement was incurred in Q4 and R&D expenses increased, resulting in 53.2 billion yen of operating income. 8

9 As for quality management system improvement at TCVS, planned works were completed as scheduled. However, we received an additional data requirement by FDA, causing 2.3 billion yen of additional cost in Q4. We originally expected a recertification by FDA to be at the end of first half of fiscal At this moment, however, it will be delayed by 6 months to the end of fiscal

10 Please let us explain the primary factors of falling short of operating income forecast, 600 billion yen. Sales performance of Nobori DES in Japan was unfavorable. The launch and/or the ramp-up of other new products, which we expected them to recover declined Nobori sales, was delayed. Increase in COGS associated with such delay of new products lowered gross profit. And finally, an additional cost for additional data requirement by FDA in regard to TCVS s quality management system improvement was incurred. 10

11 In the financial forecast for fiscal 2014, assumed exchange rates are 95 yen to the dollar and 123 yen to the Euro. Net sales forecast is 460 billion yen, up by 14 %. In this fiscal year, we aim for a double digit growth not only with Cardiac & Vascular business but also Blood Management thanks to FX rate impact as sales outside Japan play a large part of the business. Operating income forecast is 70 billion yen, up by 32%. And, considering that corporate tax returns to ordinary level, net income forecast is 42 billion yen. 11

12 In this final slide, please let us explain operating income forecast in fiscal 2013 through variance analysis against fiscal From fiscal 2012, it increases by 16.8 billion yen to 53.2 billion yen. The increase consists of 9.4 billion yen of foreign exchange as a positive factor. In spite of adverse factors such as device tax in US and increase in R&D expenses, we aim to achieve 70 billion yen of operating income by sales expansion, production cost reduction, and decrease in cost for quality management system improvement. 12

13 13

14 14

15 15

16 16

17 17

18 18

19 19

20 20

21 21

22 22

23 23